ASO Visual Abstract: Optimal Time-to-Surgery Recommendations Based on Primary Tumor Volume Regression for Patients with Resectable Esophageal Cancer After Neoadjuvant Chemoradiotherapy: A Retrospective Study
This retrospective study (https://doi.org/10.1245/s10434- 024-14941-6) included 248 patients with resectable locally advanced esophageal squamous cell carcinoma who underwent neoadjuvant chemoradiotherapy (NCRT) between May 2017 and June 2021. They underwent computed tomography scans prior and after NCRT to achieve the tumor shrinkage rate. The tumor shrinkage rate was identifed as an independent prognostic factor for progression-free survival. For all patients, no signifcant correlation was observed between time to surgery (TTS) and prognosis. However, for responders, prolonging TTS is recommended to obtain a better overall survival.
基金：
Science and Technology Department of Sichuan Province [2023YFQ0055, 2023YFS0488]
第一作者机构：[1]Univ Elect Sci & Technol China, Sch Med, Chengdu, Peoples R China[2]Univ Elect Sci & Technol China, Sichuan Canc Hosp & Inst, Affiliated Canc Hosp ,Sichuan Clin Res Ctr Canc,Ke, Sichuan Canc Ctr,Dept Radiat Oncol,Radiat Oncol, Chengdu, Peoples R China
通讯作者：
推荐引用方式(GB/T 7714)：
Li Jingqiu,Wang Qifeng.ASO Visual Abstract: Optimal Time-to-Surgery Recommendations Based on Primary Tumor Volume Regression for Patients with Resectable Esophageal Cancer After Neoadjuvant Chemoradiotherapy: A Retrospective Study[J].ANNALS OF SURGICAL ONCOLOGY.2024,31(10):6750-6751.doi:10.1245/s10434-024-15693-z.
APA：
Li, Jingqiu&Wang, Qifeng.(2024).ASO Visual Abstract: Optimal Time-to-Surgery Recommendations Based on Primary Tumor Volume Regression for Patients with Resectable Esophageal Cancer After Neoadjuvant Chemoradiotherapy: A Retrospective Study.ANNALS OF SURGICAL ONCOLOGY,31,(10)
MLA：
Li, Jingqiu,et al."ASO Visual Abstract: Optimal Time-to-Surgery Recommendations Based on Primary Tumor Volume Regression for Patients with Resectable Esophageal Cancer After Neoadjuvant Chemoradiotherapy: A Retrospective Study".ANNALS OF SURGICAL ONCOLOGY 31..10(2024):6750-6751
医学